INTRODUCTION
The human protooncogene ETS1 was identified by homology to the v-ets sequence of the E26 avian retrovirus [1] . In tion of the ETS1 gene [12] [13] [14] [15] [16] . Pulse field analysis of one tumor line demonstrated that the break of 11q23 mapped between the CD3 and ETS1 genes [17] . In addition, in two studies, isolated cases of altered ETS1 migration after restriction enzyme digestion associated with 11q23 translocations was reported [12, 13] . Other studies, however, have failed to document breakpoints in the v-ets homologous domain of ETS1 [14] [15] [16] . As part of our studies to characterize the ETS1 promoter, we examined the ETS1 promoter region for translocation in 18 cases of malignancy associated with 11q23 translocations. Consistent with recently published results demonstrating that 11q23 translocations occur at a considerable distance from the ETS1 gene [18, 19] , we failed to document any chromosome translocations associated with 11q23. However, we did identify a patient whose leukemic cell DNA consistently showed an altered ETS1 restriction enzyme fragment pattern using multiple restriction enzymes. Analysis showed that these alterations were within the promoter region of ETS1. We demonstrated that this altered restriction enzyme fragment resulted from a double strand break that mapped to the major DNaseI-hypersensitive site associated with the ETS1 promoter. Thus, our study demonstrates that altered restriction enzyme fragment migration can result from artifactual DNA breaks occurring at major DNaseI-hypersensitive sites in leukemic cells. In light of this, our work provides an important cautionary tale for workers investigating potential sites of chromosomal translocations.
MATERIALS AND METHODS

Patient Material
Bone marrow (BM) samples from patients with acute leukemia were screened for cytogenetic abnormalities as part of a routine diagnostic workup. Eighteen patients were selected based on chromosome aberrations involving 11q23 and extensive BM involvement with leukemic cells, and three patients with apparent deletions of chromosome 11 that included 11q23 were selected. Table I summarizes the cytogenetic abnormalities of these patients. Fourteen samples were supplied by the Pediatric Oncology Group, St. Louis, MO, and seven were from The University of Michigan Medical Center, Ann Arbor, Michigan. Genomic DNA was isolated, as previously described [20] , from purified leukemic cells as well as from peripheral blood (PB) cells from seven normal subjects.
Genomic Southern Blot Analysis
Genomic DNA (5 ~tg) from BM of patients with acute leukemia or white blood cells (WBC) from normal controls was digested with various restriction enzymes according to conditions suggested by the manufacturer. DNA fragments were fractionated according to size by electrophoresis on 0.7% or 0.9% agarose gels and were transferred to nitrocellulose. Membranes were baked at 80°C for 2 hours under vacuum and then prehybridized at 42°C in a solution containing 50% formamide, 5 x SSC, I x Denhardt's solution, 25 mM sodium phosphate (pH 6.5), and 250 ~g/ml Torula RNA for 3-4 hours. Hybridizations were performed for 18 to 24 hours under similar conditions except for addition of 10% dextran sulfate and 1 x 106 cpm/ml of the specific DNA probe (2 x 105-106 cpm/ng probe). The DNA probe consisted of a 442 base pair (bp} EcoRI/XbaI fragment from the 5' end of a 1,900-bp ETS1 cDNA [7] . This probe contained 58 bp of 5' untranslated region and 384 bp of ETS1 coding sequence, ending at an internal XbaI site (Fig. 1) . DNA probes were labeled by nick translation. After hybridization, membranes were washed for 10 minutes at room temperature in 2 x SSC, 0.1% SSC and then for I hour at 55°C in 0.1x SSC, 0.1% SSC. Membranes were then air-dried briefly and exposed to XAR film for varying times at -70°C with intensifying screens.
Analysis of DNaseI-Hypersensitive Sites
Nuclei were isolated from human peripheral T cells after cell lysis in RSB buffer (10 mM Tris [pH 7.4], 10 mM NaC1, 5 mM MgC12) containing 0.5% NP-40. The nuclei were resuspended to a concentration of approximately 106/ml, and equal aliquots were exposed to increasing concentrations of DNaseI for 15 minutes. DNaseI digestions were stopped by adding equal volumes of a solution containing 1% SDS, 600 mM NaC1, 20 mM Tris (pH 7.4), and 5 mM EDTA. DNA was then isolated and analyzed as outlined above.
Isolation and Characterization of Genomic Clones
Approximately 1 × 106 recombinant phage from a Sau3A partial digest of normal human PBL DNA cloned into ~,Fix (Stratagene, San Diego, CA) (a gift from Dr. J. Lowe, University of Michigan, Ann Arbor, MI) were screened with the 32p-labeled ETSl-specific DNA probe described above. Positively hybridizing clones were purified to homogeneity by restriction endonuclease and partial DNA sequence analysis.
RESULTS
11q23 is a common breakpoint observed in acute leukemia. Because the protooncogene ETS1 had been localized to 11q23, investigators have hypothesized that ETS1 rearrangement plays a role in the leukemic process [12] [13] [14] [15] [16] . Although this hypothesis was tested previously by investigators who used DNA probes homologous to the 3' region of human ETS1 to examine Southern blots of normal and leukemic DNA, we used a novel ETS1 probe from the 5' region of the human cDNA to seek rearrangements in the promoter/enhancer region of ETS1.
Southern blot analyses were performed using DNA samples from seven normal control subjects and 21 leukemic patients with chromosome 11q23 aberrations. These blots were hybridized with the 442-bp XbaI fragment isolated from the 5' terminus of the human ETS1 cDNA (Fig. 1) . If rearrangement of the ETS1 gene occurred in these patients we would expect to see novel bands in the digests of leukemic DNA as compared with control DNA. Southern blots of control DNAs digested with BamHI, EcoRI, HindIII and KpnI were prepared. After hybridization with the 5' ETS1 specific cDNA fragment and autoradiography, an identical restriction pattern was observed for the seven control samples (Fig. 2) (data not shown). Likewise, an identical restriction pattern was seen among 20 of 21 leukemic samples tested (Fig. 2) (data not shown). A novel restriction pattern was detected upon analysis of one patient with a balanced translocation involving chromosomes 11q23 and 4q21. As shown in Fig. 2 , novel 16.5 and 4.7 kb bands were noted in the BamHI and EcoRI digests respectively. To define the potential translocation detected in this patient further, we constructed a genomic map of ETS1 and, from this, designed additional genomic DNA probes. The 5' ETS1 cDNA probe was used to screen a genomic library prepared from human peripheral blood lymphocytes. Positively hybridizing phage clones were isolated and mapped with several restriction endonucleases. Clone ).1613 yielded a 6.5-kb EcoRI fragment that corresponded to the 6.5-kb band observed on Southern blots probed with the ETS1 5' fragment. This 6.5-kb fragment was subcloned (ETS 1.3) and sequenced. It contained exon 1, as determined by homology to human ETS1 cDNA sequence, as well as the promoter region of ETS1 (S. Kim and C. Thompson, manuscript in preparation). Clone X1609 yielded two BamHI fragments measuring 4 and 5 kb, respectively, and corresponding in length to two of the BamHI restriction fragment bands observed on Southern blots probed with the 5' ETS1 cDNA fragment. The two BamHI fragments were subcloned and partially sequenced. The 5-kb clone (ETS 1.1) contained the 109 bp from the 5' end of exon 2, and the 4-kb (ETS 1.2) clone contained the remaining 9 bp of exon 2 as well as all of exon 3 (Fig. 3) . To determine which fragment had acquired an altered migration pattern in the DNA from patient (PT) 13, we used the ETS 1.3 genomic clone containing the ETS1 promoter/enhancer region, first exon, and 5' end of the first intron to isolate two ETSl-specific genomic DNA probes that flanked the first exon. The first probe (5' ETS 1.3) contained the 850-bp EcoRI-HindIII fragment from the 5' end of ETS 1.3. The second probe (3' ETS 1.3) contained the 500-bp XbaI-EcoRI fragment from the 3' end of ETS 1.3 (Fig. 3) .
Southern blots containing restriction enzyme-digested DNA from PT 13 leukemia cells were consecutively hybridized with the 5' and 3' ETS 1.3 probes. In BamHI-restricted DNA, the 3' ETS 1.3 probe detected both the germline 22 kb fragment and the novel 16.5 kb fragment detected with the original 5' ETS1 cDNA probe (Fig. 4) , whereas the 5' ETS 1.3 fragment detected both the germline 22-kb fragment and a novel band of 5.6 kb (Fig. 5) . In EcoRI-restricted DNA, the 3' ETS 1.3 probe detected the germline 6.5-kb fragment and novel 4.7-kb fragment detected with the original 5' ETS1 cDNA probe, whereas the 5' ETS 1.3 fragment detected both the germline 6.5-kb fragment and a 1.8-kb fragment. As shown in Fig. 5 , the novel BamHI and EcoRI sites detected in this single patient were localized to the same site in the genomic map of ETS1 and, in both cases, the size of the novel bands detected by probes 5' and 3' of the breakpoint equaled the size of the parental fragment detected in control DNA by both probes. Likewise, data obtained using two additional restriction enzymes localized a DNA break to this same site (SacI and KpnI, data not shown). Thus, all four enzymes confirmed we were detecting a DNA break rather than a translocation. To determine whether the break was an isolated artifact of DNA preparation, we obtained a second sample of leukemic cells from this patient and reanalyzed it by Southern blot. The results were identical to those detected initially, implying that the DNA break could be reproducibly observed in serial leukemic samples.
We then performed DNaseI-hypersensitive site analysis of the ETS1 promoter region, and noted that a major site of nuclease sensitivity mapped to the position of the breakpoint detected in the DNA isolated from the leukemic cells of patient 13 (Fig. 6) , suggesting that the DNA break occurred artifactually in preparation of DNA from the frozen leukemic cells and demonstrating that rearrangements in or around the ETSl promoter are not involved in 11q23 translocations. In one patient, however, we detected a DNA break which we mapped to the major DNaseI-hypersensitive site present in the ETS1 promoter.
DISCUSSION
The association between chromosome aberrations and protooncogenes have yielded important insights into the etiology of several human hematopoietic malignancies, including B-cell neoplasms and chronic myelogenous leukemia. Because the protooncogene ETS1 has been localized near the leukemia-specific breakpoint 11q23, that ETS1 was hypothesized to play a role in the leukemic process. Indeed, several cases of altered ETS1 restriction enzyme fragments were reported in cases of 11q23 translocation [12, 13] . As part of our analysis of ETS1 gene expression, we had an opportunity to examine the ETS1 promoter region for rearrangement in 18 patients with 11q23 translocations. None of these patients had any evidence of translocation associated with the ETS1 gene. Therefore, our data are consistent with recently published reports that localize the 11q23 breakpoint at least several hundred kilobases centromeric of the ETS1 gene [18, 19] .
In the course of our study, however, using multiple restriction enzymes, we identified a patient whose leukemic cell DNA consistently showed an altered ETS1 restriction enzyme fragment. These observations resulted from a breakpoint that mapped in the promoter region of ETS1. Such a DNA break must be artifactual because a chromosome with a double-strand break will undergo loss of the centromeredistal fragment during a subsequent cell division. DNaseIhypersensitive site analysis showed that the break mapped to the major nuclease-sensitive site in the promoter region of ETS1. Therefore, apparent alteration in the size of the restriction enzyme fragment alone is not sufficient justification to conclude that a chromosome translocation has occurred in the vicinity of a probe. Even if nonleukemic tissue from the patient fails to show a similar fragment, an endogenous nuclease acting at DNaseI-hypersensitive sites can create artifactual alterations in restriction fragment lengths in tumor samples. In this light, this work provides an important cautionary tale for workers investigating potential sites of chromosome translocation. Previous data reporting breakpoints involving ETS1 may have resulted from DNA breaks at nuclease-hypersensitive sites. I'
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B Figure 5 Genomic map of the ETS1 promoter region in relation to patient PT 13 (SA}. Southern blot of 5 ~g of genomic DNA from NC3 and patient 13 digested with BamHI and EcoRI and probed consecutively with the ETS1 cDNA fragment containing the first exon described in the legend to Fig, 1 {B} and the 5' ETS 1.3 genomic fragment described in the legend to Fig. 3 (C}. The arrows in B highlight the novel BamHI and EcoRI bands measuring 16.5 and 4.7 kb, respectively (also shown in Fig. 2} . Likewise, the arrows in C highlight the novel BamHI and EcoRI bands measuring 5.6 and 1.8 kb, respectively. Novel BamHI and EcoRI sites detected in patient 13 digests (solid and broken arrows, respectively, 5A). Figure 6 The DNA breakpoint observed in patient 13 occurs at the major DNAsel-hypersensitive site in the ETS1 promoter/enhancer. Southern blot of 5 ~tg genomic DNA from normal human peripheral blood T cells treated with varying concentrations of DNAsel (0, 1, and 2.5 ~g/ml) and DNA from patient 13, digested with EcoRI, and probed with the 3' ETS 1.3 probe. The DNA break in the promoter region of ETS1 in the DNA from leukemic cells from patient 13 maps to the major DNAseI-hypersensitive site in the ETS1 promoter.
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